Optimal  	Optimal  	 JJ	B-NP
management  	management  	 NN	I-NP
of  	of  	 IN	O
recurrent  	recurrent  	 JJ	O
ovarian  	ovarian  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
The  	The  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
an  	an  	 DT	O
optimal  	optimal  	 JJ	B-NP
management  	management  	 NN	I-NP
approach  	approach  	 NN	I-NP
in  	in  	 IN	O
recurrent  	recurrent  	 JJ	O
ovarian  	ovarian  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
requires  	requires  	 VBZ	O
careful  	careful  	 JJ	O
consideration  	consideration  	 NN	B-NP
of  	of  	 IN	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
important  	important  	 JJ	O
factors  	factors  	 NNS	O
including  	including  	 VBG	O
( 	( 	 -LRB-	O
a 	a 	 LS	O
)  	)  	 -RRB-	O
response  	response  	 NN	O
to  	to  	 TO	O
and  	and  	 CC	O
severity 	severity 	 CD	B-NP
/ 	/ 	 CD	I-NP
persistence  	persistence  	 NN	I-NP
of  	of  	 IN	O
toxicity  	toxicity  	 VBG	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
prior  	prior  	 JJ	O
therapy 	therapy 	 NN	O
,  	,  	 ,	O
( 	( 	 -LRB-	O
b 	b 	 LS	O
)  	)  	 -RRB-	O
existence  	existence  	 NN	O
of  	of  	 IN	O
relevant  	relevant  	 JJ	O
trial  	trial  	 NN	B-NP
data  	data  	 NNS	I-NP
( 	( 	 -LRB-	O
particularly  	particularly  	 RB	O
phase  	phase  	 VB	O
3  	3  	 CD	O
studies 	studies 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
( 	( 	 -LRB-	O
c 	c 	 LS	O
)  	)  	 -RRB-	O
patient  	patient  	 JJ	O
interest  	interest  	 NN	O
in  	in  	 IN	O
participating  	participating  	 VBG	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials 	trials 	 NNS	I-NP
,  	,  	 ,	O
( 	( 	 -LRB-	O
d 	d 	 LS	O
)  	)  	 -RRB-	O
cost  	cost  	 NN	O
of  	of  	 IN	O
( 	( 	 -LRB-	O
and  	and  	 CC	O
ability  	ability  	 NN	B-NP
to  	to  	 TO	O
pay  	pay  	 VB	O
for 	for 	 IN	O
)  	)  	 -RRB-	O
particular  	particular  	 JJ	O
anti-neoplastic  	anti-neoplastic  	 JJ	B-NP
drug  	drug  	 NN	I-NP
regimens 	regimens 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
( 	( 	 -LRB-	O
e 	e 	 LS	O
)  	)  	 -RRB-	O
patient  	patient  	 JJ	O
choice 	choice 	 NN	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
likely  	likely  	 RB	O
that  	that  	 IN	O
the  	the  	 DT	O
increasing  	increasing  	 JJ	O
availability  	availability  	 NN	O
of  	of  	 IN	O
biologically  	biologically  	 JJ	O
active  	active  	 JJ	O
novel  	novel  	 NN	O
agents  	agents  	 NNS	O
( 	( 	 -LRB-	O
and  	and  	 CC	O
combination  	combination  	 NN	B-NP
programs 	programs 	 NNS	I-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
this  	this  	 DT	O
clinical  	clinical  	 JJ	B-NP
setting  	setting  	 NN	I-NP
will  	will  	 MD	O
add  	add  	 VB	O
to  	to  	 TO	O
the  	the  	 DT	O
difficulty  	difficulty  	 NN	O
of  	of  	 IN	O
defining  	defining  	 FW	O
optimal  	optimal  	 FW	B-NP
therapy  	therapy  	 FW	I-NP
in  	in  	 FW	O
recurrent 	recurrent 	 FW	B-NP
/ 	/ 	 FW	I-NP
resistant  	resistant  	 FW	I-NP
ovarian  	ovarian  	 FW	I-NP
cancer 	cancer 	 NN	I-NP
,  	,  	 ,	O
which 	which 	 WDT	O
,  	,  	 ,	O
in  	in  	 IN	O
many  	many  	 JJ	O
individuals 	individuals 	 NNS	O
,  	,  	 ,	O
can  	can  	 MD	O
be  	be  	 VB	O
reasonably  	reasonably  	 RB	O
considered  	considered  	 VBN	O
a  	a  	 DT	O
very  	very  	 RB	O
serious  	serious  	 JJ	B-NP
chronic  	chronic  	 JJ	I-NP
disease  	disease  	 NN	I-NP
process 	process 	 NN	I-NP
.  	.  	 .	O
